It begins below the obesity-trial floor because appetite and gastrointestinal effects need time to adapt before escalation. At 5 mg, both GIP and GLP-1 are clinically active
This is the broader theme in Metos companion piece: peptides and GLP-1s are not inherently competitors
FDA Advisory Committee Votes to Ease Peptide Restrictions: What the July 2026 Vote on BPC-157, KPV, TB-500, and MOTS-c Actually Means An FDA advisory committee voted on July 23, 2026 to recommend easing restrictions on four peptides BPC-157, KPV, TB-500, and MOTS-c
Discussed this exact topic with another coach just few days ago
Who the combination is, and isn't, for A reasonable case for considering the addition of AOD-9604 to a GLP-1 protocol looks like this